Welcome to HealthyDogPetCo Blog

Sitemap xml

510 .

Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.

Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R. . JAMA. 2021 Sep 8. doi: 10.1001/jama.2021.15494. Online ahead of print. JAMA. 2021. PMID: 34495304 No abstract available. .

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.

Ashraf S, Ashraf S, Farooq I, Ashraf S, Ashraf M, Imran MA, Kalsoom L, Akmal R, Ghufran M, Rafique S, Akram MK, Habib Z, Siddiqui UN, Ahmad A, Arshad S, Virk MAR, Gul M, Awais AB, Hassan M, Sherazi SSH, Safdar Z, Munir I, Khalid H, Munir K, Majeed N, Alahmadi YM, Humayun A, Saboor QA, Ahmad A, Ashraf M, Izhar M; DOCTORS LOUNGE Consortium. .

470 . Schuliga M, et al. Am J Physiol Lung Cell Mol Physiol. 2021 Sep 15. doi: 10.1152/ajplung.00574.2020. Online ahead of print. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 34524912 .

Page

News

Page

News

Gluten intolerance a significant risk factor
Infectious disease of the uterus
Absence of an individual specific disease

Page

News